Drugs / 68Ga-NODAGA-E[c(RGDyK)]2
68Ga-NODAGA-E[c(RGDyK)]2
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02970786 | Nov 2016 → Jun 2017 | breast cancer, neuroendocrine carcinoma, ovarian cancer | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03505346 | Jan 2024 → Dec 2025 | myocardial ischemia | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase 2 | NCT03445884 | Feb 2018 → Jul 2020 | acute myocardial infarction | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 2 | NCT03271281 | Dec 2017 → Dec 2021 | neuroendocrine neoplasm | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03655977 | Sep 2018 → Sep 2021 | cervical cancer | Rigshospitalet, Denmark | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NODAGA-E(c[RGDyK])2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02970786 ↗ |
| Modality | Diagnostic / imaging agent | “radio tracer 68Ga-NODAGA-E\[c(RGDyK)\]2 for PET imaging of angiogenesis” NCT02970786 ↗ |
| Route | Intravenous | “administered IV” NCT03445884 ↗ |